Journal Scans
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
Lapatinib/Letrozole Superior to Letrozole in HER2+/HR+ Metastatic Breast Cancer
S Johnston, J Pippen Jr, X Pivot, M Lichinitser, S Sadeghi, V Dieras, HL Gomez, G Romieu, A Manikhas, MJ Kennedy, MF Press, J Maltzman, A Florance, L O'Rourke, C Oliva, S Stein, M Pegram
20090828
2009 Sept 28
J Clin Oncol
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
J Clin Oncol. 2009 Sept 28; Epub ahead of print, S Johnston, J Pippen Jr, X Pivot, M Lichinitser, S Sadeghi, V Dieras, HL Gomez, G Romieu, A Manikhas, MJ Kennedy, MF Press, J Maltzman, A Florance, L O'Rourke, C Oliva, S Stein, M Pegram
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Resistance to endocrine therapy often hampers successful treatment of hormone receptor (HR)–positive metastatic breast cancer (MBC). Cross-talk between epidermal growth factor receptor (EGFR) ErbB1 and human EGFR ErbB2 (ie, HER2) and the estrogen-receptor (ER) pathway is thought to play a key role in resistance to endocrine therapy. Thus, a rationale exists for multitargeted therapy to overcome resistant disease. Lapatinib is an orally administered dual tyrosine kinase inhibitor that targets both...
